Boston University biomedical engineers find chink in bacter...(ng the cell. In addition to potentia...)
Navigation Links
Boston University biomedical engineers find chink in bacteria's armor
Date:9/6/2007
ng the cell.
In addition to potentially making bacteria more vulnerable to current drugs, this finding may revitalize development of antibiotic drugs sidelined because of narrow differences between therapeutic and toxic doses. Such drugs might re-enter the pipeline, if this free-radical producing pathway is exploited to lower the therapeutic dose, making formerly dangerous drugs safer.
'/>"/>
| Contact: Mike Seele mseele@bu.edu 617-353-9766 Boston University Source:Eurekalert |
Related biology news :
1. Boston University biomedical engineers win major grant for pursuit of the $1,000 Genome
2. University of Manchester makes made-to-measure skin and bones a reality using inkjet printers
3. New protein discovered by Hebrew University researchers
4. Next Generation Body Scanner Launched By The University Of Manchester
5. Roundup®highly lethal to amphibians, finds University of Pittsburgh researcher
6. Green catalyst destroys pesticides and munitions toxins, finds Carnegie Mellon University
7. University of Nevada, Reno research team discovers hormone that causes malaria mosquito to urinate
8. Carnegie Mellon University research reveals how cells process large genes
9. University of Delaware researchers develop cancer nanobomb
10. University of Arizona plant scientists to unravel maize genome
11. Team led by Carnegie Mellon University scientist finds first evidence of a living memory trace
Post Your Comments:
Breaking Biology News(10 mins):Self-destructing bacteria improve renewable biofuel production 2Self-destructing bacteria improve renewable biofuel production 3New York autopsies show 2009 H1N1 influenza virus damages entire airway 2New York autopsies show 2009 H1N1 influenza virus damages entire airway 3Delivering medicine directly into a tumor 2Loss of tumor supressor gene essential to transforming benign nerve tumors into cancers 10334 1Loss of tumor supressor gene essential to transforming benign nerve tumors into cancers 10334 2Loss of tumor supressor gene essential to transforming benign nerve tumors into cancers 10334 3Magnetic nanotags spot cancer in mice earlier than methods now in clinical use 10332 1Magnetic nanotags spot cancer in mice earlier than methods now in clinical use 10332 2Magnetic nanotags spot cancer in mice earlier than methods now in clinical use 10332 3Magnetic nanotags spot cancer in mice earlier than methods now in clinical use 10332 4Magnetic nanotags spot cancer in mice earlier than methods now in clinical use 10332 5Conservation targets too small to stop extinction 10330 1Conservation targets too small to stop extinction 10330 2
Other Biology News:Symposia selected for Entomological Society of America meeting 2Symposia selected for Entomological Society of America meeting 3Symposia selected for Entomological Society of America meeting 4When industrious ants go too far 2
Breaking Biology Technology:Myriant Technologies LLC Selected for $50 Million Award for Succinic Acid Biorefinery Project 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6EUCODIS Bioscience Appoints Thomas Fischer as New CEO 2Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 2Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 3
[0] Myriant Technologies LLC Selected for $50 Million Award for Succinic Acid Biorefinery Project[0] AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology[0] EUCODIS Bioscience Appoints Thomas Fischer as New CEO[0] Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc.
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |